Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr;4(2):353-61.
doi: 10.2147/tcrm.s1266.

New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide

F Braido  1 , C Lagasio, Img Piroddi, I Baiardini, Gw Canonica
Affiliations

New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide

F Braido et al. Ther Clin Risk Manag. 2008 Apr.

Abstract

Allergic rhinitis (AR) is a chronic inflammatory respiratory disease affecting 5%-50% of the worldwide population and its prevalence is increasing (Herman 2007). In addition, AR is associated with asthma and other co-morbidities such as conjunctivitis and sinusitis. The main symptoms are nasal congestion, rhinorrea, sneezing, itching, and post-nasal drainage induced after allergen exposure by an IgE-mediated inflammation of the membranes lining the nose. AR is not a life-threatening disease, but it has been shown to have a significant impact on quality of life. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines propose a classification of AR in intermittent and persistent, each graded as mild or moderate-severe, and provide a stepwise approach to the treatment. Inhaled steroids and antihistamine are the main tools in AR therapy but more safe and effective drugs are, however, needed. Inhaled steroid ciclesonide appears to be safe and effective.

Keywords: allergic rhinitis; asthma; ciclesonide; quality of life.

PubMed Disclaimer

Conflict of interest statement

Disclosures The authors have no conflicts of interest to disclose.

References

    1. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2001;106:253–9. - PubMed
    1. ALTANA Pharma. Ciclesonide nasal spray. Draft Labeling Text 1.14.1.3. 2006
    1. Andersson P, Ryrfeldt A. Biotransformation of the topical glucorticosteroids budesonide and beclomethasone 17,21 dipropionate in human liver and lung homogenate. J Pharm Pharmacol. 1984;763:765–36. - PubMed
    1. Andersson M, Svensson C, Persson C, et al. Dose-dependent effects of budesonide aqueous nasal spray on symptoms in daily nasal allergen challenge model. Ann Allergy Asthma Immunol. 2000;279:283–85. - PubMed
    1. [ARIA] Allergic Rhinitis and its Impact on Asthma guidelines. 2007. Accessed 31 Jan 2008. URL: http://www.whiar.org/ - PubMed